Efficacy News and Research

RSS

Myocarditis risk from mRNA COVID vaccines re-evaluated in Canadian study (Research Now Withdrawn)

Scientists from the University of Ottawa, Canada, have recently estimated the prevalence of myocarditis/pericarditis in individuals recently immunized with mRNA-based coronavirus disease 2019 (COVID-19) vaccines. The analysis reveals a prevalence of 10 myopericarditis cases for every 10,000 vaccine doses. The study is currently available on the medRxiv* preprint server.

20 Sep 2021

Development of a potential pan-variant aerosol to manage COVID-19

Researchers hypothesized that if APN01 could be directly introduced into the airways of an infected person, it could locally neutralize SARS-CoV-2.

19 Sep 2021

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

A new study utilized MVA to develop vaccine candidates that were subsequently evaluated in animal models of congenital cytomegalovirus disease.

19 Sep 2021

Study shows efficacy of mRNA vaccines against SARS-CoV-2 in individuals with obesity

A new study evaluated the antibody response against SARS-CoV-2 between individuals who were affected by abdominal obesity (AO) and those who were not,

19 Sep 2021

New data shows benefit of drug combination for metastatic castration resistant prostate cancer

New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC).

18 Sep 2021

A 100% French nasal vaccine against SARS-CoV-2 to move into the clinical phase in 2022

In contrast to intramuscular vaccines, only nasal vaccines are able to block the virus in the nose by inducing local immunity in the nasal mucosa, i.e. the portal of entry and multiplication of the virus.

18 Sep 2021

What pushed Israel out of herd immunity?

Scientists have recently tried to explain the factors that could be responsible for the recent outbreaks of COVID-19 in Israel.

17 Sep 2021

Humoral and cellular response to COVID-19 vaccines in patients with IBD

A new study published in the preprint server medRxiv* aimed to evaluate the humoral and cellular response to COVID-19 vaccine in patients with IBD undergoing biologic or immunomodulatory therapy.

17 Sep 2021

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

A study evaluates the efficacy of a mAb to prevent disease progression in non-hospitalized persons with symptomatic SARS-CoV-2 infection.

17 Sep 2021

COVID-19 infections in Australian healthcare workers

A team of researchers performed state-wide SARS-CoV-2 genomic epidemiological investigations to recognize health care worker transmission dynamics and support optimizing healthcare system readiness for similar future outbreaks.

17 Sep 2021

COVID-19 variants keep getting better at traveling through the air, study shows

Results of a new study led by the University of Maryland School of Public Health show that people infected with the virus that causes COVID-19 exhale infectious virus in their breath – and those infected with the Alpha variant (the dominant strain circulating at the time this study was conducted) put 43 to 100 times more virus into the air than people infected with the original strains of the virus.

17 Sep 2021

Organs-on-chips for personalized medicine and to assess drug efficacy

Organs-on-chips could be used to assess drug efficacy and support personalized medicine, write Adrian Roth and colleagues in a Perspective.

17 Sep 2021

Three doses of inactivated BBIBP-CorV SARS-CoV-2 vaccine induce robust B and T cell responses

To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.

17 Sep 2021

Study points to a possible new approach for treating MRSA superbug

A study released in STEM CELLS Translational Medicine, by researchers at the Baker Institute for Animal Health, part of Cornell University's College of Veterinary Medicine, Ithaca, N.Y., details in a relevant ex vivo model how treating wounds with the secretion of a type of stem cell called mesenchymal stromal cell (MSC) effectively reduced methicillin-resistant Staphylococcus aureus – better known as MRSA viability and stimulated the surrounding skin cells to build up a defense against the bacterial invader.

16 Sep 2021

Pfizer vaccine induces strong immunity in elderly with prior COVID-19

A new study discusses the vaccination response in elderly who were vaccinated with one dose of the Pfizer vaccine 15 months after contracting COVID-19.

16 Sep 2021

How effective is the Johnson & Johnson COVID-19 vaccine?

A new study demonstrates the real-world efficacy of this vaccine, its stability over time, as well as its efficacy against the SARS-CoV-2 Delta variant.

16 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

UTSW researchers discover how vitamin A enters immune cells in the intestines

Immunologists and geneticists at UT Southwestern Medical Center have discovered how vitamin A enters immune cells in the intestines – findings that could offer insight to treat digestive diseases and perhaps help improve the efficacy of some vaccines.

16 Sep 2021

Experts raise questions about routine use of surrogate endpoints for drug approvals

A growing number of drugs are being approved on the basis of indirect ('surrogate') measures that do not always reliably predict outcomes that matter most to patients, such as living longer or feeling better.

16 Sep 2021

Single dose of typhoid conjugate vaccine found to be safe and effective in Malawian kids

A new study, published today in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi.

16 Sep 2021